Clinical Trials Browser

Phase 2 × Diabetes Mellitus, Insulin-Dependent, 12 × 1 year × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT07416058 2026-02-17

PHOENIX

Phase 2 Not yet recruiting

61 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07410975 2026-02-13

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Phase 2 Recruiting

54 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03993379 2025-12-26

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Phase 2 Terminated

3 enrolled 7 charts

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms, Recurrence

NCT07243951 2025-11-24

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

75 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Liver Neoplasms

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Phase 2 Completed

14 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT05608044 2025-09-04

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2 Active not recruiting

234 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Phase 2 Not yet recruiting

48 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07128251 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Phase 2 Not yet recruiting

47 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Clinical Trials

NEST-1

Tremelimumab

PHOENIX

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)